Telangana Unveils Ambitious Next-Generation Life Sciences Policy for Global Impact 2026-30
In a bid to position itself as a global leader in life sciences, the Government of Telangana, India, has officially unveiled its Next-Generation Life Sciences Policy for the period 2026-30 during the World Economic Forum in Davos on January 22, 2026. The policy marks a significant shift in focus from large-scale manufacturing to value-added, innovative contributions to the global health sector. With a clear ambition to rank among the top five global life sciences hubs by 2030, Telangana aims to attract $25 billion in investments while creating up to 500,000 high-quality jobs.
This transformative strategy is designed not only to enhance the state’s industrial depth but also to bolster research, development, and innovative initiatives. Telangana is already a favored destination for global life sciences giants like Amgen, Sanofi, Bristol Myers Squibb, and Eli Lilly, which have established or expanded their R&D and digital centers in Hyderabad. These developments underscore the region’s robust talent pool and conducive infrastructure, which are pivotal for fostering innovation.
Chief Minister M. A. Revanth Reddy and Minister for IT and Industries M. D. Sridhar Babu were present at the launch, signifying the state's commitment to accelerating its evolution from a reliance on global supply chains to becoming a pioneer of advanced therapies and platforms.
"We are building one of the most reliable and transformative bioscience ecosystems globally, which will enhance global health from Telangana," said Reddy. The policy emphasizes cutting-edge science and advanced manufacturing platforms, specifically targeting cellular and gene therapies, precision fermentation, and next-generation modalities. Furthermore, it aims to strengthen broader ecosystems around clinical research, pharmaceutical services, diagnostics, medical electronics, and digital health, positioning Telangana for attraction of global life sciences centers.
Implementation of this policy will leverage world-class infrastructure, including the Green Pharma City, ten Pharma Villages, an expanded Genome Valley, and improved Medical Devices Park. A dedicated life sciences innovation fund potentially reaching up to 10 billion Indian Rupees (approximately $100 million) will catalyze innovation in startup and growth phases, support high-tech enterprises, and attract private and institutional investment.
Additionally, the establishment of the Telangana School of Life Sciences represents a commitment to building a globally recognized university focused on research, education, and talent development, primed for future challenges.
Telangana’s aspirations are rooted in a mature, globally connected ecosystem that is already operating on a significant scale. Over the past two decades, the state has transitioned from basic manufacturing to a comprehensive life sciences hub. Currently, it hosts over 2,000 life sciences companies and has one of the highest concentrations of USFDA-approved pharmaceutical facilities in the world, meeting a third of global vaccine demand. Its companies play a crucial role in fortifying global health supply chains, especially concerning vaccines, complex generics, biologics, and biosimilars.
The unveiling of the Next-Generation Life Sciences Policy is a testament to Telangana's determination to lead in health innovation, emphasizing a collaborative, cross-border approach to harnessing global capital and shared innovation programs. By prioritizing groundbreaking science and advanced manufacturing, Telangana is set to become a premier destination for life sciences, reinforcing its status as a key player in the global health landscape.
This transformative strategy is designed not only to enhance the state’s industrial depth but also to bolster research, development, and innovative initiatives. Telangana is already a favored destination for global life sciences giants like Amgen, Sanofi, Bristol Myers Squibb, and Eli Lilly, which have established or expanded their R&D and digital centers in Hyderabad. These developments underscore the region’s robust talent pool and conducive infrastructure, which are pivotal for fostering innovation.
Chief Minister M. A. Revanth Reddy and Minister for IT and Industries M. D. Sridhar Babu were present at the launch, signifying the state's commitment to accelerating its evolution from a reliance on global supply chains to becoming a pioneer of advanced therapies and platforms.
"We are building one of the most reliable and transformative bioscience ecosystems globally, which will enhance global health from Telangana," said Reddy. The policy emphasizes cutting-edge science and advanced manufacturing platforms, specifically targeting cellular and gene therapies, precision fermentation, and next-generation modalities. Furthermore, it aims to strengthen broader ecosystems around clinical research, pharmaceutical services, diagnostics, medical electronics, and digital health, positioning Telangana for attraction of global life sciences centers.
Implementation of this policy will leverage world-class infrastructure, including the Green Pharma City, ten Pharma Villages, an expanded Genome Valley, and improved Medical Devices Park. A dedicated life sciences innovation fund potentially reaching up to 10 billion Indian Rupees (approximately $100 million) will catalyze innovation in startup and growth phases, support high-tech enterprises, and attract private and institutional investment.
Additionally, the establishment of the Telangana School of Life Sciences represents a commitment to building a globally recognized university focused on research, education, and talent development, primed for future challenges.
Telangana’s aspirations are rooted in a mature, globally connected ecosystem that is already operating on a significant scale. Over the past two decades, the state has transitioned from basic manufacturing to a comprehensive life sciences hub. Currently, it hosts over 2,000 life sciences companies and has one of the highest concentrations of USFDA-approved pharmaceutical facilities in the world, meeting a third of global vaccine demand. Its companies play a crucial role in fortifying global health supply chains, especially concerning vaccines, complex generics, biologics, and biosimilars.
The unveiling of the Next-Generation Life Sciences Policy is a testament to Telangana's determination to lead in health innovation, emphasizing a collaborative, cross-border approach to harnessing global capital and shared innovation programs. By prioritizing groundbreaking science and advanced manufacturing, Telangana is set to become a premier destination for life sciences, reinforcing its status as a key player in the global health landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.